Discontinued — last reported Q3 '19

Other

Lease Payments

Vertex Pharmaceuticals Lease Payments remained flat by 0.0% to $45.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 61.4%, from $28.38M to $45.80M. Over 2 years (FY 2023 to FY 2025), Lease Payments shows an upward trend with a 70.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ1 2019
Last reportedQ3 2019

How to read this metric

Significant increases in cash payments without corresponding revenue growth may indicate tightening liquidity or rising fixed cost commitments.

Detailed definition

This metric represents the actual cash outflow associated with operating lease liabilities during the period. It is a ke...

Peer comparison

Reported in the 'Supplemental Cash Flow Information' section of the lease disclosures.

Metric ID: is_cvx_operating_lease_payments_cash

Historical Data

3 years
 FY'23FY'24FY'25
Value$62.80M$113.50M$183.20M
YoY Change+80.7%+61.4%
Range$62.80M$183.20M
CAGR+70.8%
Avg YoY Growth+71.1%
Median YoY Growth+71.1%
Current Streak2+ years growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's lease payments?
Vertex Pharmaceuticals (VRTX) reported lease payments of $45.80M in Q4 2025.
How has Vertex Pharmaceuticals's lease payments changed year-over-year?
Vertex Pharmaceuticals's lease payments increased by 61.4% year-over-year, from $28.38M to $45.80M.
What is the long-term trend for Vertex Pharmaceuticals's lease payments?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's lease payments has grown at a 70.8% compound annual growth rate (CAGR), from $62.80M to $183.20M.
What does lease payments mean?
The actual cash paid to satisfy operating lease obligations.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.